TABLE 1.

Characteristics of ORSA PFTsa

Name of PFTTotal no. of U.S. ORSA strains in PFT (%)MLST and allelic profilebspa typecClone named
USA100292 (44)ST 5, 1- 4- 1- 4- 12- 1- 10TJMBMDMGMKUSA100 ORSA II
USA80045 (6.7)ST 5, 1- 4- 1- 4- 12- 1- 10TJMBMDMGMKUSA800 ORSA IVe
TJMBMDMGMKST 5 ORSA I
USA20057 (8.5)ST 36, 2- 2- 2- 2- 3- 3- 2WGKAKAOMQQQUSA200 ORSA II
USA40042 (6.3)ST 1, 1- 1- 1- 1- 1- 1- 1UJJJFEUSA400 ORSA IVe
USA30091 (13.6)ST 8, 3- 3- 1- 1- 4- 4- 3YHGF MBQBLOUSA300 ORSA IVe
USA50034 (5.1)ST 8, 3- 3- 1- 1- 4- 4- 3YHGC MBQBLOUSA500 ORSA IV,e USA500 ORSA II
ST 8, 3- 3- 1- 1- 4- 4- 3YHGC MBQBLOST8 ORSA I, ST8 ORSA IV, ST8 ORSA III
ST 250, 3- 3- 1- 1- 4- 4- 16YH GF MBQBLOST250 ORSA I
ST 247, 3- 3- 1- 12- 4- 4- 16YHFGF MBQBLOST247 ORSA I
USA60023 (3.4)ST 45, 10- 14- 8- 6- 10- 3- 2A2AKEEMBKBUSA600 ORSA II
ST 45, 10- 14- 8- 6- 10- 3- 2A2AKEEMBKBUSA600 ORSA IVe
USA70038 (5.7)ST 72, 1- 4- 1- 8- 4- 4- 3UJGFMGGMUSA700 ORSA IVe
Unnamed14 (2)Not testedZDMDMNKB
Unnamed3ST 239, 2- 3- 1- 1- 4- 4- 3WGKAOMQST239 ORSA III
ST 240, 2- 3- 1- 1- 2- 4- 3WGKAOMQST240 ORSA III
Unnamed0ST 22, 7- 6- 1- 5- 8- 8- 6TJEJN12MN12MOMST 22 ORSA IV
Published name (references)Antimicrobial resistance patternfPublished isolates (reference[s])Comments
New York/Japan (1, 51)β-Lactams, ery, cli, lvx7 U.S. VISAs (22, 60, 65), 2 U.S. VRSAs (8, 9, 11), Japan VISA Mu50 (28), Korea VISA (33), CMRSA-2,g BK2464 (1, 13, 51), PA237 (52), JP48 (1)Predominate U.S health care-associated PFT; endemic in many U.S. hospitals
Pediatric (24, 55)β-LactamsHDE1 (55), HDE288 (13, 55), COB94 (24)
β-Lactams, ery, cli, genERMSA3h
β-Lactams, ery, cli, lvx, genEMRSA16hSecond most common U.S. health care-associated PFT
β-Lactams, eryMW2 (6, 42)Community onset; isolates from (i) Native Americans (25), (ii) children without risk factors (6, 27, 42), (iii) early Australian community onset (39, 44), and (iv) San Francisco urban poor (12)
β-Lactams, eryCommunity onset; isolates from (i) correctional facilities in Miss. (7), Ga., Tenn., Tex., and Calif. (10) and (ii) athletic teams in Pa. and Calif. (10)
β-Lactams, ery, cli, tet, lvx, gen, sxtU.S. VISA (Ohio)
Archaic/Iberian (46, 47)β-Lactams, ery, tetEMRSA2, EMRSA6, EMRSA7, EMRSA12, EMRSA13, EMRSA14h
Archaic/Iberian (46, 47, 57)β-Lactams, ery, tetEMRSA 8, PER34 (57), NCTC10442 (31)SCCmec I identified (31)
Archaic/Iberian (46, 47, 57)β-Lactams, ery, cli, tet, lvx, gen, sxtEMRSA5,h E2125 (13), HPV 107 (13, 57) France VISA (50), Scotland 463
β-Lactams, ery, cli, lvxCMRSA-1g
β-Lactams, eryPLN49 (2)Tenn. food outbreak (34)
β-LactamsSecond genotype at Miss. correction facility outbreak (7); hospital-associated mec+, susceptible phenotypei
β-Lactams, eryAlaska surveillance; Vt. wrestling team outbreak (37)
Brazilian/Hungarian (2, 46, 63)β-Lactams, ery, cli, tet, chl, lvx, gen, sxtEMRSA1, EMRSA11, EMRSA4,h HU25 (2), HSJ216, HUSA304 (13), 85/2082 (31), CMRSA-3,g Scotland 461SCCmec III identified (31)
Brazilian/Hungarian (2, 46, 63)β-Lactams, ery, cli, tet, chl, lvx, gen, sxtEMRSA9h
β-LactamsEMRSA15h (54)Endemic to United Kingdom (54)
  • a PFT is based on SmaI PFGE with ≥80% similarity identified on an UPGMA-derived dendrogram using Dice coefficients.

  • b Allelic profile is based on the DNA sequences of seven housekeeping genes: arcC, aroE, glpF, gmk, pta, tpi, and yqiL.

  • c DNA sequence of polymorphic region of protein A gene. The spa type motif is shown in boldface.

  • d The clone name consists of the following three parts: PFT or MLST sequence type, the oxacillin phenotype (all are ORSA in this table), and the SCCmec type (when available).

  • e Isolates in this PFT subgroup were susceptible to spectinomycin.

  • f β-Lactams (oxacillin and penicillin); chl, chloramphenicol; cli, clindamycin; ery, erythromycin; gen, gentamicin; lvx, levofloxacin; tet, tetracycline; sxt, trimethoprim-sulfamethoxazole.

  • g CMRSA strains are epidemic type strains from Canada (59). Four strains are included in this study.

  • h EMRSA strains are epidemic type strains from the United Kingdom (16, 54). Fifteen strains are included in this study.

  • i J. Block, M. F. Orlando, L. K. McDougal, L. Jevitt, W. M. Dunne, S. Fitzsimmons, and J. Gerst, Abstr. 103rd Gen. Meet. Am. Soc. Microbiol. 2003, abstr. C-088.